| | |
|
        | |
  | |
|
| Investors Home | Management Team | Board of Directors | Events Calendar | SEC Filings | Financial Statements | FAQ | |
| | | |
|  | |  |
| | | |
| | | |
| | | |
| | |
Download Corporate Profile  2005 Letter to Stockholders
|
|
ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs.
We apply new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identify proprietary and related molecules for better patient treatment. Investor Relations Contact: Nicole Jones (617) 778-2266 ir@ziopharm.com |
|
Please visit the OTC Bulletin Board for the latest ZIOP stock quote: http://www.otcbb.com/asp/Info_Center.asp?symbol=ziop Transfer Agent: American Stock Transfer and Trust 1601 15th Avenue New York, NY 11219 877-248-6417 | | |
  Forbes.com article Is Randal J. Kirk Biotech’s Best Investor? February 22, 2011 More Forbes.com article A Biotech Billionaire And His Radical DNA Drug That Kills Cancer From Within January 7, 2011 More Forbes.com article Thornton returns to Ziopharm Oncology January 4, 2011 More Businessweek article July 23, 2007 issue More Businessweek article May 5, 2008 issue More Forbes.com article May 9, 2008 issue More ZIO-101 listed as 100 Great Investigational Drugs by R&D Directions More ZIO-201 listed as 100 Great Investigational Drugs by R&D Directions More  Robert W. Baird 2006 Focus on Oncology Conference August 2, 2006 New York, NY Click here for Webcast Click here for Presentation Wall Street Analyst Forum June 14, 2006 New York, NY Click here for Webcast Click here for Presentation ASCO June 2-6, 2006 Atlanta, GA Click here for Presentation Information Request  Investor Kit  Click to receive news alerts |
|
©2005 ZIOPHARM Oncology, Inc. | Privacy Policy |